Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
RICHLAND, Wash. & CORALVILLE,
Iowa–(BUSINESS WIRE)–Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology
company and innovator in seed brachytherapy, today announced the successful
completion of the merger with privately-held Viewpoint Molecular Targeting,
Inc. The combined companies’ focus will be the advancement of cancer treatments
using radiation, radiopharmaceuticals, and imaging technologies so that
precision, targeted medical doses are delivered directly to cancer patient
tumor sites. Viewpoint Molecular Targeting CEO Thijs Spoor has been named Chief
Executive Officer and outgoing Isoray CEO Lori Woods assumed the role of Chairperson
of the Board of Directors of the combined companies. The closing of the
all-stock transaction became effective on February 3, 2023.
To read more please visit:
Source: Isoray